EA201201614A1 - Инъекционная лекарственная форма флупиртина - Google Patents
Инъекционная лекарственная форма флупиртинаInfo
- Publication number
- EA201201614A1 EA201201614A1 EA201201614A EA201201614A EA201201614A1 EA 201201614 A1 EA201201614 A1 EA 201201614A1 EA 201201614 A EA201201614 A EA 201201614A EA 201201614 A EA201201614 A EA 201201614A EA 201201614 A1 EA201201614 A1 EA 201201614A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- flupirtine
- lyophilisate
- pharmaceutical composition
- flupirtina
- parenteral administration
- Prior art date
Links
- 238000002347 injection Methods 0.000 title 1
- 239000007924 injection Substances 0.000 title 1
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 abstract 5
- 229960003667 flupirtine Drugs 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 238000007911 parenteral administration Methods 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение касается флупиртинсодержащего лиофилизата, применения этого лиофилизата для производства фармацевтической композиции для парентерального применения, способа получения флупиртинсодержащей фармацевтической композиции для парентерального применения и способа получения флупиртинсодержащего лиофилизата, а также флупиртинсодержащей фармацевтической композиции, полученной с использованием этого лиофилизата. С этой целью описывается лиофилизат, содержащий в качестве активного компонента флупиртин в форме физиологически приемлемой соли, имеющей растворимость в воде по крайней мере 2,5 мг/мл, предпочтительно по крайней мере 5 мг/мл, особенно предпочтительно по крайней мере 10 мг/мл, и один или более циклодекстринов и/или производных циклодекстрина, и который может использоваться для получения фармацевтической композиции для парентерального применения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010030053A DE102010030053A1 (de) | 2010-06-14 | 2010-06-14 | Injizierbare Darreichungsform von Flupirtin |
PCT/EP2011/059863 WO2011157719A1 (en) | 2010-06-14 | 2011-06-14 | An injectable dosage form of flupirtine |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201201614A1 true EA201201614A1 (ru) | 2013-04-30 |
EA023081B1 EA023081B1 (ru) | 2016-04-29 |
Family
ID=44310408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201614A EA023081B1 (ru) | 2010-06-14 | 2011-06-14 | Инъекционная лекарственная форма флупиртина |
Country Status (7)
Country | Link |
---|---|
US (1) | US20130096163A1 (ru) |
EP (1) | EP2579856A1 (ru) |
CN (1) | CN103037848A (ru) |
CA (1) | CA2799489A1 (ru) |
DE (1) | DE102010030053A1 (ru) |
EA (1) | EA023081B1 (ru) |
WO (1) | WO2011157719A1 (ru) |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1795858C2 (de) | 1968-07-19 | 1979-01-11 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | Benzylaminopyridine |
DE3133519A1 (de) | 1980-09-13 | 1982-06-09 | Degussa Ag, 6000 Frankfurt | "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat" |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
DE3416609A1 (de) * | 1984-05-05 | 1985-11-07 | Degussa Ag, 6000 Frankfurt | 2-amino-3-ethoxycarbonylamino-6-(p-fluor-benzylamino)- pyridin-gluconat und pharmazeutische zubereitungen, die diese substanz enthalten |
IN172468B (ru) | 1990-07-14 | 1993-08-14 | Asta Medica Ag | |
DE9321574U1 (de) | 1992-03-11 | 2000-06-29 | Asta Medica Ag | Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen |
DE4319649A1 (de) | 1993-03-18 | 1994-09-22 | Asta Medica Ag | Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe |
DE4327516A1 (de) | 1993-08-17 | 1995-02-23 | Asta Medica Ag | Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin |
DE19541405A1 (de) | 1995-11-07 | 1997-05-15 | Asta Medica Ag | Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen |
DE10048969A1 (de) | 2000-08-23 | 2002-03-14 | Mueller Schwefe Gerhard | Verwendung von Flupirtin zur Tinnitusbehandlung |
DE10327674A1 (de) * | 2003-06-20 | 2005-01-05 | Awd.Pharma Gmbh & Co. Kg | Injizierbare Darreichungsform von Flupirtin |
WO2008020584A1 (fr) * | 2006-08-14 | 2008-02-21 | Eisai R & D Management Co., Ltd. | Préparation lyophilisée stable |
US20090046775A1 (en) | 2007-08-17 | 2009-02-19 | Arvind Thiagarajan | System And Method For Delivery Of Electronic Data |
EP2278999A4 (en) * | 2008-04-21 | 2015-04-22 | Otonomy Inc | EARLY TREATMENT FORMULATIONS FOR THE TREATMENT OF EARLY DISEASES AND DRESSES |
US8222282B2 (en) * | 2008-06-09 | 2012-07-17 | Teva Pharmaceuticals Usa, Inc. | Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine |
-
2010
- 2010-06-14 DE DE102010030053A patent/DE102010030053A1/de not_active Ceased
-
2011
- 2011-06-14 EP EP11725441.7A patent/EP2579856A1/en not_active Withdrawn
- 2011-06-14 CA CA2799489A patent/CA2799489A1/en not_active Abandoned
- 2011-06-14 US US13/704,277 patent/US20130096163A1/en not_active Abandoned
- 2011-06-14 WO PCT/EP2011/059863 patent/WO2011157719A1/en active Application Filing
- 2011-06-14 CN CN2011800296490A patent/CN103037848A/zh active Pending
- 2011-06-14 EA EA201201614A patent/EA023081B1/ru not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE102010030053A1 (de) | 2011-12-15 |
CN103037848A (zh) | 2013-04-10 |
EP2579856A1 (en) | 2013-04-17 |
EA023081B1 (ru) | 2016-04-29 |
WO2011157719A1 (en) | 2011-12-22 |
CA2799489A1 (en) | 2011-12-22 |
US20130096163A1 (en) | 2013-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
EA201291168A1 (ru) | Фармацевтические композиции и способы их получения | |
EA201270505A1 (ru) | Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение | |
PH12015500407B1 (en) | Methods of treating hypertriglyceridemia | |
EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
EA201692443A1 (ru) | Водная фармацевтическая композиция тапентадола для перорального введения | |
UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
TW200744677A (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
EA201171088A1 (ru) | Лечение дискинезии при различных расстройствах | |
EA201491994A1 (ru) | Способы комплексообразования с циклодекстринами для введения пептидных протеасомных ингибиторов в фармацевтические составы | |
UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
EA201690183A1 (ru) | Замещенные пиразолопиридинамины | |
CY1117483T1 (el) | Συνθεσεις τροποποιημενης αποδεσμευσης επαλρεστατης ή ενος παραγωγου αυτης και μεθοδοι για χρηση των ιδιων | |
DK2244703T3 (da) | Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier | |
MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
EA201390950A1 (ru) | Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой | |
UA93365C2 (ru) | Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты) | |
UA109544C2 (uk) | Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення | |
SMT201300112B (it) | Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene | |
EA201490233A8 (ru) | Стабильные лекарственные формы артеролана и пиперахина | |
MY160005A (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |